| Title |
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
|
|---|---|
| Published in |
Dermatology and Therapy, March 2018
|
| DOI | 10.1007/s13555-018-0230-9 |
| Pubmed ID | |
| Authors |
Jose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel, Robert Strohal |
| Abstract |
Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting approximately 1-5% of the population worldwide) and is associated with significant morbidity. The introduction of biologic therapies has improved the management of this disease. Multiple biologic medicines that block cytokine signaling, including tumor necrosis factor (TNF) antagonists (adalimumab, etanercept, and infliximab) and inhibitors of interleukin (IL)-17 (brodalumab, ixekizumab, and secukinumab), IL-23 (guselkumab), or IL-12/23 (ustekinumab), are approved for the treatment of psoriasis. Despite the clinical benefits associated with use of biologics in psoriasis, many patients are not treated with biologic therapy, and access to treatment may be limited for various reasons, such as high treatment costs. Patents for many biologics have expired or will soon expire, and biosimilar versions of these agents are available or in development. A biosimilar is a biological product that is highly similar to an approved biologic (i.e., originator or reference) product, and has no clinically meaningful differences in safety, purity, or potency when compared with the reference product. Biosimilars may offer less expensive treatment options for patients with psoriasis; they also may increase access to and address problems with underutilization of biologic therapy. Biosimilar development and approval follows a well-regulated process in many countries, with guidelines developed by the European Medicines Agency, US Food and Drug Administration, and World Health Organization. Currently, several anti-TNF biosimilars are available for use in patients with psoriasis, and other monoclonal antibodies are in development. This review provides dermatologists and those who treat and/or manage psoriasis with a working knowledge of the scientific principles of biosimilar development and approval. It also examines real-world experience with biosimilars available for or used in dermatology that will enable physicians to make informed treatment decisions for their patients with psoriasis. Pfizer Inc. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 20% |
| United Kingdom | 2 | 20% |
| Spain | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Scientists | 1 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 111 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 15% |
| Student > Master | 16 | 14% |
| Student > Ph. D. Student | 10 | 9% |
| Student > Postgraduate | 8 | 7% |
| Student > Doctoral Student | 8 | 7% |
| Other | 24 | 22% |
| Unknown | 28 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 15% |
| Biochemistry, Genetics and Molecular Biology | 7 | 6% |
| Nursing and Health Professions | 3 | 3% |
| Computer Science | 3 | 3% |
| Other | 17 | 15% |
| Unknown | 30 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2023.
All research outputs
#2,078,832
of 24,147,581 outputs
Outputs from Dermatology and Therapy
#78
of 846 outputs
Outputs of similar age
#45,390
of 336,852 outputs
Outputs of similar age from Dermatology and Therapy
#5
of 15 outputs
Altmetric has tracked 24,147,581 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 846 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,852 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.